Artemis Pharmaceuticals and Merck, Qiagen, Protein Design Labs and Cyntellect, MWG Biotech, and Benitec and Artemis Pharmaceuticals | GenomeWeb

Artemis Signs Deal to Create Knockdown Mice for Merck

Artemis Pharmaceuticals said this week that it has signed a deal to develop RNAi-modified genetically engineered mice for use by Merck for in vivo functional analysis of selected disease-related genes.

Under the deal, Merck will provide shRNA sequences that correspond to genes that may play a role in human diseases. Artemis will use the shRNAs and its RNAi technology to generate mice in which the genes are down regulated.

Financial terms of the arrangement were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.